Article Information
History
- January 24, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Takehisa Noguchi1,¶,
- Kyosuke Hidaka1,¶,
- Satsuki Kobayashi1,¶,
- Kenjiro Matsumoto1,
- Makoto Yoshioka2,
- Shyh-Ming Yang3,
- David J. Maloney3 and
- Shinichi Kato1,*
- 1Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan
- 2ConverGene LLC, 3093 Beverly Lane, Unit C, Cambridge, MD 21613, USA
- 3National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, USA
- ↵*Corresponding author: Email: skato{at}mb.kyoto-phu.ac.jp (SK)
↵¶ These authors contributed equally to this work
Posted January 24, 2020.
Ameliorative effect of a quinazoline-based bromodomain inhibitor, CN210, on experimentally-induced Crohn’s disease-like murine ileitis via inhibition of inflammatory cytokine expression
